Gisle Langslet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9112667/publications.pdf

Version: 2024-02-01

49	4,896	236925	214800
papers	citations	25 h-index	47 g-index

50	50	50	5015
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499.	27.0	1,838
2	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	13.7	615
3	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	2.2	395
4	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	2.8	316
5	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care, 2015, 38, 355-364.	8.6	197
6	Long-term Low-Density Lipoprotein Cholesterolâ€“Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. JAMA Cardiology, 2017, 2, 598.	6.1	137
7	Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2010, 55, 1121-1126.	2.8	136
8	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 2132-2146.	2.8	101
9	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet, The, 2015, 385, 2153-2161.	13.7	92
10	A phase III randomized trial evaluating alirocumab 300Âmg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis, 2016, 254, 254-262.	0.8	91
11	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. Cardiovascular Drugs and Therapy, 2014, 28, 281-289.	2.6	86
12	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 455-463.	11.4	84
13	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 359-366.	1.6	84
14	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 195-203.e4.	1.5	56
15	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 390-396.e8.	1.5	51
16	Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2015, 13, 477-488.	1.5	50
17	Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis, 2014, 233, 561-567.	0.8	48
18	Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. Atherosclerosis, 2018, 278, 307-314.	0.8	45

#	Article	IF	Citations
19	Efficacy and safety of rosuvastatin therapy inÂchildren and adolescents with familial hypercholesterolemia: Results from the CHARONÂstudy. Journal of Clinical Lipidology, 2015, 9, 741-750.	1.5	42
20	The heart failure burden of type 2 diabetes mellitusâ€"a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	3.9	41
21	Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. Journal of Pediatrics, 2015, 167, 338-343.e5.	1.8	40
22	LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 279-286.	1.5	39
23	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1338-1346.e7.	1.5	38
24	A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1153-1162.e3.	1.5	30
25	Treatment goal attainment in children with familial hypercholesterolemia: A cohort study ofÂ302 children in Norway. Journal of Clinical Lipidology, 2018, 12, 375-382.	1.5	29
26	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. Journal of Clinical Lipidology, 2018, 12, 1199-1207.	1.5	24
27	Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2013, 11, 1061-1066.	1.5	23
28	Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. Journal of Clinical Lipidology, 2015, 9, 778-785.	1.5	19
29	Sex differences in cholesterol levels from birth to 19Âyears of age may lead to increased cholesterol burden in females with FH. Journal of Clinical Lipidology, 2018, 12, 748-755.e2.	1.5	19
30	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.6	19
31	Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. American Journal of Preventive Cardiology, 2021, 6, 100180.	3.0	16
32	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	2.8	15
33	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Therapy, 2016, 7, 269-278.	2.5	14
34	Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. Journal of Clinical Lipidology, 2019, 13, 138-147.	1.5	14
35	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^{Â®}. Diabetes and Vascular Disease Research, 2020, 17, 147916412097525.	2.0	9
36	Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea. European Heart Journal, 2016, 37, 1357-1359.	2.2	8

#	Article	IF	Citations
37	Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. Journal of Clinical Lipidology, 2021, 15, 134-141.	1.5	6
38	Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia. Atherosclerosis, 2021, 316, 48-52.	0.8	5
39	Treatment goals in familial hypercholesterolaemiaâ€”time to consider low-density lipoprotein-cholesterol burden. European Journal of Preventive Cardiology, 2022, 29, 2278-2280.	1.8	5
40	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5253-5262.	3.6	4
41	Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels. Journal of Clinical Lipidology, 2018, 12, 1327-1328.	1.5	3
42	Familial hypercholesterolemia and young patientsâ€™ thoughts on own condition and treatment. Patient Education and Counseling, 2019, 102, 1005-1012.	2.2	3
43	Alirocumab dosing patterns during 40Âmonths of open-label treatment in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1463-1470.	1.5	2
44	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. Cardiovascular Drugs and Therapy, 2020, 34, 515-523.	2.6	2
45	Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. Journal of Clinical Lipidology, 2021, 15, 375-378.	1.5	2
46	Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. Frontiers in Pharmacology, 2020, 11, 560958.	3.5	2
47	Response by Kusters et al to Letter Regarding Article, â€œEffect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)â€• Circulation, 2018, 137, 641-642.	1.6	1
48	Authorâ€™s response to: letter to the editor. Heart Failure Reviews, 2018, 23, 819-819.	3.9	0
49	Response to the editor. Heart Failure Reviews, 2018, 23, 819.	3.9	0